Adial Becomes Azora Therapeutics, Swaps Ticker to AZR With New CEO and $32M in Tow
ADIL has more than doubled off its 52-week low of $1.31.
Summary
Adial Pharmaceuticals is now Azora Therapeutics, and the stock trades under AZR on the Nasdaq Capital Market starting Thursday. The rebrand follows the June acquisition of Azora, whose co-founders Matt Davidson and Julie Saiki take over as CEO and chief strategy officer; Celia Economides is CFO, David Rubenstein chief scientist and Ajay Duggal consulting chief medical officer. The company closed a roughly $32 million private placement alongside the merger and can draw another $32 million tied to launching a Phase 1 trial of AT177 in ulcerative colitis, expected in the first half. The new leadership inherits a balance sheet already flagged in filings: an August 8-K/A showed Azora with $282K of cash and a going concern warning, and the October 10-Q/A quantified a potential $51.9 million Series A preferred settlement against $22.0 million of cash. The name and ticker change are largely cosmetic, but the leadership slate and the AT177 timeline are the first concrete operating plan from the combined company.
At the time of this announcement, ADIL was trading at $5.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.3M. The 52-week trading range was $1.31 to $9.53. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.